Unity Biotechnology (NASDAQ:UBX – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.15, Yahoo Finance reports.
Unity Biotechnology Stock Performance
UBX stock traded up $0.07 during trading on Thursday, hitting $1.48. 48,924 shares of the company’s stock traded hands, compared to its average volume of 70,860. Unity Biotechnology has a 52 week low of $1.22 and a 52 week high of $2.67. The stock has a market capitalization of $24.85 million, a price-to-earnings ratio of -0.56 and a beta of 0.84. The business has a fifty day simple moving average of $1.45 and a 200 day simple moving average of $1.57.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Unity Biotechnology in a report on Thursday.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Further Reading
- Five stocks we like better than Unity Biotechnology
- Investing in large cap stocks: Diving into big caps
- Owens-Corning Stock: Good Value or Recession Red Flag?
- Roth IRA Calculator: Calculate Your Potential Returns
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
